ReviewJournal of molecular neuroscience : MN2026
Biomarker Based ARIA Stress Test: A Proposed Conceptual Framework for Dynamic Biomarker-Guided ARIA Risk Stratification in Anti-Amyloid Immunotherapy for Alzheimer's Disease.
Review in Journal of molecular neuroscience : MN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While anti-amyloid immunotherapy has shown clinical benefit, amyloid-related imaging abnormalities (ARIA), comprising vasogenic edema (ARIA-E) and microhemorrhages (ARIA-H), represent the principal safety limitation. This paper presents a theoretical construct not yet based on empirical data. As a theoretical construct, we systematically synthesize current published findings on ARIA pathophysiology, plasma biomarker biology (glial fibrillary acidic protein [GFAP], amyloid-beta [Aβ] 42/40 ratio, neurofilament light chain [NfL], and phosphorylated tau [p-tau217]), and clinical trial outcomes. We propose that ARIA is fundamentally a kinetic-not static-pathological event, driven by the velocity of immune-mediated amyloid clearance. The Neuro-Pharmacological Kinetic Stress Test (NPKST) measures plasma biomarker velocity (rate of change per unit time) at Days 3-4 and 7 following the first therapeutic dose. A rapid spike in plasma GFAP velocity (ΔpGFAP/Δt), a precipitous decline in Aβ42/40 ratio velocity, and early NfL elevation constitute early biochemical signatures of individuals at high risk for clinically significant ARIA before macroscopic MRI changes are detectable. The Biomarker Velocity Composite Index (BVCI) stratifies patients into Low, Intermediate, and High Velocity tiers, each linked to specific dosing modification protocols. The cardiac stress test analogy provides the conceptual scaffold: the first therapeutic dose serves as the 'pharmacological stress,' and the BVCI captures the individual's dynamic neuro-immune-vascular response phenotype. This proposed theoretical framework, if validated through future pilot studies and the KINETIC-ARIA trial, would shift ARIA prevention from reactive MRI surveillance to proactive biomarker-guided risk management. Long-term monitoring of potential ARIA effects is warranted.
Indexed as
Identifiers
42298214What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.